Key facts
- Mirador Therapeutics’s last known valuation is $1.0B (Jan 2026).
- It has raised $735.0M across 2 recorded rounds; the latest was Later Stage VC ($333.0M) in Feb 2024.
- Notable investors include Alexandria Venture Investments, OrbiMed, ARCH Venture Partners, Venrock, Blue Owl Capital — 17 tracked in total.
- Mirador Therapeutics has filed 2 Form Ds with the SEC, most recently Apr 2024 ($80.0M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Mirador Therapeutics
Funding rounds
2 roundsAbout Mirador Therapeutics
Developer of precision medicine technologies designed to address unmet needs in immune-mediated and inflammatory diseases. The company offers features such as a proprietary data analytics engine that harmonizes extensive patient molecular profiles, identifies novel therapeutic targets, and develops diagnostics, enabling researchers and healthcare providers to create targeted therapies based on individual genetics, ultimately improving treatment outcomes for patients suffering from chronic conditions.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2024
- Website
- miradortx.com/
- Ownership
- Privately Held (backing)
Mirador Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mirador Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mirador Therapeutics in its N-PORT filings yet. We sweep new filings monthly.